NCT07432347Recruiting
Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This is a national, observational, retrospective, cross-sectional, non-profit study focused on patients with HCC. The study aims to characterize the expression and function of novel noncoding regulatory transcripts, including those containing TEsin the microenvironment of liver tumors, with emphasis on their role in T cell dysfunction.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 270 (estimated)
- First submitted
- 19 Feb 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 31 Jan 2029
- Lead sponsor
- Niguarda Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07432347
What you commit to
- Study type: Observational
- Planned participants: 270
- From 1 Jan 2026 to the primary completion date, 31 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Histological/radiological (LR-4 o 5)diagnosis of hepatocellular carcinoma (HCC).
- Solid tumor fresh tissue availability from HCC biospy or surgical resectionas per standard clinical practice, and/orHCC FFPE archival samples availability.
- Capability of understanding and signing an inform consent form.
- Known hepatits B and C status, including HBeAg (positive or negative), viral load (HBVDNA e HCV-RNA), HCV genotype, whether sustained virological response (SVR)was obtainedand potential antiviral treatments received (including direct antiretroviral therapy(DAA)and interferon). These parameters will be exploited to stratify patients and analyze the impact of the virological status on microenvironmental immunological features, with particular regards to immunesuppression mechanisms.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST GOM Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.